Scholarlink

Background <p>Patients with Autoimmune Encephalitis (AE) commonly report poor quality of life. There is a lack of evidence on whether clinician-rated outcome measures adequately capture patient-reported experiences. This study aimed to characterise long-term quality of life in AE patients and examine its relationship with clinician-rated disability (modified Rankin Score, mRS) and symptom severity (Clinical Assessment Scale in Autoimmune Encephalitis, CASE).</p> Methods <p>Patients with AE were recruited through the Australian Autoimmune Encephalitis Consortium Project. Patients with completed NeuroQoL instruments, as well as CASE and/or mRS scores within 6 months of the NeuroQoL were included.</p> Results <p>Fifty-four patients with AE (50% female, median age at symptom onset = 49.70 years) completed the NeuroQoL instruments at a median of 50 months (IQR: 18.25–87.50 months) post-disease onset. The median CASE score was 2 (IQR: 0.0–3.0). The median mRS was 1.5 (IQR: 1.0–2.0). In the total AE sample, CASE scores were positively associated with all NeuroQoL domains (<i>r</i> = .42−.53), except Fatigue (<i>r</i> = .28). Total NeuroQoL, Cognitive Function, Satisfaction in Social Roles and Activities, and Stigma T-scores were significantly higher in seropositive AE patients with an mRS &gt; 2 (<i>d</i> = 0.94–1.66). The mRS significantly predicted most NeuroQoL domains in the total AE sample, and the CASE score explained little or no additional variance over and above mRS scores. Similarly, the CASE score was significantly associated with most NeuroQoL domains, with no additional variance explained by mRS scores.</p> Discussion <p>The relationships between clinician-rated outcomes and domains of quality of life varied from weak to moderate. This highlights the importance of integrating clinical measures and patient-reported outcomes when assessing outcomes post-AE.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis Consortium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月31日

查看全文
  • Christina Kazzi,
  • Nabil Seery,
  • Sarah Griffith,
  • Robb Wesselingh,
  • Tiffany Rushen,
  • Tracie H. Tan,
  • Katherine Y. Ko,
  • Liora ter Horst,
  • Genevieve Skinner,
  • Laurie McLaughlin,
  • Hannah Ford,
  • Catherine Meade,
  • Marie O’Shea,
  • Katherine Buzzard,
  • Mirasol Forcadela,
  • Andrew Duncan,
  • Anneke van der Walt,
  • Wendyl D’Souza,
  • Udaya Senvieratne,
  • Richard Macdonell,
  • Sudarshini Ramanathan,
  • Stefan Blum,
  • Stephen W. Reddel,
  • Todd A. Hardy,
  • Helmut Butzkueven,
  • Terence J. O’Brien,
  • Rubina Alpitsis,
  • Charles B. Malpas,
  • Mastura Monif

摘要

Background

Patients with Autoimmune Encephalitis (AE) commonly report poor quality of life. There is a lack of evidence on whether clinician-rated outcome measures adequately capture patient-reported experiences. This study aimed to characterise long-term quality of life in AE patients and examine its relationship with clinician-rated disability (modified Rankin Score, mRS) and symptom severity (Clinical Assessment Scale in Autoimmune Encephalitis, CASE).

Methods

Patients with AE were recruited through the Australian Autoimmune Encephalitis Consortium Project. Patients with completed NeuroQoL instruments, as well as CASE and/or mRS scores within 6 months of the NeuroQoL were included.

Results

Fifty-four patients with AE (50% female, median age at symptom onset = 49.70 years) completed the NeuroQoL instruments at a median of 50 months (IQR: 18.25–87.50 months) post-disease onset. The median CASE score was 2 (IQR: 0.0–3.0). The median mRS was 1.5 (IQR: 1.0–2.0). In the total AE sample, CASE scores were positively associated with all NeuroQoL domains (r = .42−.53), except Fatigue (r = .28). Total NeuroQoL, Cognitive Function, Satisfaction in Social Roles and Activities, and Stigma T-scores were significantly higher in seropositive AE patients with an mRS > 2 (d = 0.94–1.66). The mRS significantly predicted most NeuroQoL domains in the total AE sample, and the CASE score explained little or no additional variance over and above mRS scores. Similarly, the CASE score was significantly associated with most NeuroQoL domains, with no additional variance explained by mRS scores.

Discussion

The relationships between clinician-rated outcomes and domains of quality of life varied from weak to moderate. This highlights the importance of integrating clinical measures and patient-reported outcomes when assessing outcomes post-AE.